Core Viewpoint - The company emphasizes that its stock price in the secondary market is influenced by macroeconomic conditions, industry policies, and investor risk preferences [2] Group 1 - The company's production and operational activities are normal [2] - The company is focused on its core responsibilities and is striving to improve its management practices [2] - The company aims to achieve high-quality development [2] Group 2 - The stock price of the listed company is affected by various factors [2] - Investors are advised to invest rationally and be aware of investment risks [2]

格隆汇2月12日丨博雅生物(300294.SZ)在投资者互动平台表示，截至目前，公司暂无更名计划。 ...

Group 1 - The core issue revolves around corporate governance and performance concerns at Boya Bio-Pharmaceutical (300294), with investor skepticism regarding executive pay amidst operational losses [1] - The company emphasized its focus on the blood products core business, indicating uncertainty in external mergers and acquisitions, while disclosing that the controlling shareholder, China Resources Pharmaceutical, has no new holding plans [1] - Boya Bio-Pharmaceutical's net profit for 2025 is expected to decline significantly, underperforming compared to its peers among six listed companies [1] Group 2 - Boya Bio-Pharmaceutical's stock price has shown a downward trend, closing at 22.33 yuan on February 12, 2026, with a daily drop of 0.76% and a cumulative decline of 0.53% over the past five days [2] - The stock has experienced a 4.08% decline over the past 20 days, with a net outflow of 4.74 million yuan in principal funds on the latest trading day [2] - The stock's short-term technical support level is at 22.01 yuan, while the resistance level is at 23.75 yuan, indicating weaker performance compared to the pharmaceutical and biotechnology sector, which fell by 0.44% [2]

证券日报网讯2月11日，博雅生物（300294）在互动平台回答投资者提问时表示，公司2026年2月10日含 信用账户合并名册的股东人数为31681户。 ...

（文章来源：证券日报） 证券日报网讯 2月11日，博雅生物在互动平台回答投资者提问时表示，公司二级市场股票价格受到宏观 环境、行业政策、投资者风险偏好等因素影响，敬请投资者理性投资，注意投资风险。 ...

Core Viewpoint - China Resources Pharmaceutical Group Limited (referred to as "China Resources Pharmaceutical") announced the potential sale of approximately 17.87% equity in Hefei Tianmai Biotechnology Development Co., Ltd. (referred to as "Tianmai Biotechnology") through public listing, with a base price of approximately 1.42 billion yuan [1] Group 1: Company Actions - China Resources Pharmaceutical's wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated the sale of its stake in Tianmai Biotechnology [1] - The company holds a total of 23.75% equity in Tianmai Biotechnology, with China Resources Pharmaceutical Investment being the largest shareholder at 20% [2] Group 2: Industry Context - The sale is seen as a strategic move to focus on core business by divesting non-core assets, influenced by the failure of Tianmai Biotechnology's oral insulin product to gain market approval [3] - Tianmai Biotechnology's application for the oral insulin capsule (ORMD-0801) was not approved by the National Medical Products Administration, impacting its market position [3] Group 3: Financial Performance - Since 2025, China Resources has been actively selling its pharmaceutical assets, indicating a shift in strategic direction [4] - In 2024, China Resources Pharmaceutical reported revenue of approximately 257.7 billion yuan, a year-on-year increase of 5.3%, but a net profit decline of 13.06% to approximately 3.351 billion yuan [4] - For the first half of 2025, revenue was approximately 131.9 billion yuan, a year-on-year increase of 2.54%, while net profit fell by 20.30% to approximately 2.077 billion yuan [4]

Core Viewpoint - China Resources Pharmaceutical announced the potential sale of approximately 17.87% equity in Tianmai Biotechnology, with a listing price of around RMB 1.42 billion, marking its exit from being a core shareholder after a 10-year investment [1][4]. Group 1: Company Overview - Tianmai Biotechnology, established in 2010, focuses on the development of diabetes-related products and services [1]. - The company has a diverse shareholder structure with 21 shareholders, where China Resources Pharmaceutical Investment holds a 20% stake, making it the largest and core shareholder [1]. Group 2: Investment History - China Resources Pharmaceutical initially invested in Tianmai Biotechnology due to its focus on the significant diabetes market and the potential of oral insulin ORM-D-0801 [3]. - The investment history includes a previous sale of 14.12% equity for approximately HKD 1.147 billion in 2017, triggered by Tianmai's failure to obtain GMP certification [3][4]. Group 3: Product Development - Tianmai Biotechnology has partnered with Singapore's Vanier Company for joint research and development of biopharmaceuticals, establishing bases in Israel and China [2]. - The company developed ORM-D-0801, an oral insulin product aimed at treating type 2 diabetes, which faced challenges in clinical trials [6]. Group 4: Market Challenges - The oral insulin ORM-D-0801 failed to meet primary and secondary endpoints in a Phase III trial, leading to its rejection by the National Medical Products Administration in December 2025 [7]. - Following the failure of ORM-D-0801, Tianmai Biotechnology must return to the traditional insulin market, facing competition from established players without the scale or technology reserves [7]. Group 5: Strategic Decisions - The decision to sell Tianmai Biotechnology's stake reflects China Resources Pharmaceutical's broader strategy of divesting non-core assets amid changing market conditions [8]. - This strategic move indicates a proactive approach to risk management and resource allocation in a complex market environment [8].

证券日报网讯 2月9日，博雅生物在互动平台回答投资者提问时表示，公司坚定践行华润"1246"模式， 以"四个重塑"为抓手，在复杂多变的市场环境中攻坚克难。自2021年华润医药控股以来，公司在原料血 浆端拓展、终端掌控、研发创新、国际化等方面均保持稳健发展，具体经营情况及财务状况请参阅公司 公告。截至目前，公司暂无迁址至北京或上海计划。 （文章来源：证券日报） ...

格隆汇2月9日丨博雅生物(300294.SZ)在投资者互动平台表示，公司坚定践行华润"1246"模式，以"四个 重塑"为抓手，在复杂多变的市场环境中攻坚克难。自2021年华润医药控股以来，公司在原料血浆端拓 展、终端掌控、研发创新、国际化等方面均保持稳健发展，具体经营情况及财务状况请参阅公司公告。 截至目前，公司暂无迁址至北京或上海计划。 ...

Core Insights - The article highlights the fundraising activities of various investment funds in January 2026, with a total of 17 fundraising events amounting to over 270 billion RMB [2]. Fundraising Activities - Hengxu Capital completed the first closing of its fourth flagship fund, raising over 2 billion RMB, with a target final closing of 3.5 billion RMB [5][7]. - Dongfang Jiafu National SME Development Sub-Fund successfully completed its first closing of 1.6 billion RMB, with a total target of 2 billion RMB, focusing on advanced manufacturing, new materials, and health sectors [8][9]. - Zhangzhou Capital Operations Group and CICC established a healthcare fund with a total scale of 1 billion RMB, targeting traditional Chinese medicine and biomedicine [10][11]. - China Resources Capital launched a 1 billion RMB fund focused on chemical innovation drugs and high-end medical devices [12]. - Caitong Capital's two funds completed expansion, raising over 2.4 billion RMB to support the development of Taizhou Bay New Area [13]. - Kaibo Capital's Kaibo Nord Energy Storage Fund completed registration with a scale of 400 million RMB, focusing on independent energy storage projects [14][15]. - Deth Capital initiated a 500 million RMB fund aimed at the cultural and film sectors [18]. - The Baiyin Specialty Industry Fund, managed by Jincheng Capital, successfully registered with a scale of 200 million RMB, focusing on local specialty industries [19][20]. - Guangzhou Industrial Control Group launched a 1 billion RMB fund to support early-stage technology companies [21]. - Hushan Capital's new fund focusing on AI and semiconductor industries completed its first closing at 400 million RMB [22]. - Hubei Port and Shipping Development Fund completed expansion, reaching a scale of 2.8 billion RMB [24]. - Luxin Venture Capital initiated a 1 billion RMB fund targeting the artificial intelligence sector [26][27]. - Electric Science Investment established a 2 billion RMB electronic basic industry fund [28]. - Shangcheng Capital launched a 10 billion RMB fund to support AI and embodied intelligence industries [29]. - Beigong Investment and Jizhi Future established a 200 million RMB venture capital fund focusing on AI and new information technology [30]. - SPD Bank launched the "Puchuang Huazhang" science and technology direct investment fund with a scale of 500 million RMB [32][33]. - The "Golden Seed" fund for university student entrepreneurship was established with a scale of 45 million RMB [34][35].